Search results for: 'android ed point termin forecast 2014'
- Related search terms
- Point-of-Care Testing (POCT) Market
- Point-of-Care Testing Market, Global, 2024–2031
- Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026
- Point-of-Care Ultrasound Imaging Technology Ecosystem,
- Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026.
-
23 Jun 2016  |  North America  |  Market Research
Growth Opportunities in the US Point-of-care Testing Market
Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics
The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...
$4,950.00
Special Price $3,712.50 save 25 %
-
05 Oct 2018  |  North America  |  Market Research
US Point-of-Care Testing Infectious Disease Market, Forecast to 2022
CLIA Waived Molecular POCT, Coupled with Upcoming Diseases Like Sepsis, Lyme Disease, New Strains of Influenza—H1, H3, and H7, will Drive Growth
Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...
$1,500.00
Special Price $1,125.00 save 25 %
-
19 Dec 2022  |  North America  |  Market Research
PCR-based PoC Platforms for Infectious Disease Testing Growth Opportunities
Multimodal and Multiplex Platforms are Expanding the Molecular PoC Testing Ecosystem
Since the onset of the COVID-19 pandemic, molecular diagnostics mergers/acquisition transactions and product launches for infectious disease testing are indicating a pivot toward a new direction or an enhancement of portfolios. The emergence of saliva sample testing and the transition to PCR-based syndromic and direct-to-consumer testing for respir...
$2,450.00
Special Price $1,837.50 save 25 %
-
14 Sep 2020  |  North America  |  Market Research
Smartphone-based Solutions Spur the Global Infectious Disease Point-of-Care Testing Market, Forecast to 2024
COVID-19 and STDs among Millennials Speed Development of Miniaturized POCT Devices and Alternate Care Sites to Enable Transformational Growth
The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...
$4,950.00
Special Price $3,712.50 save 25 %
-
11 Dec 2020  |  North America  |  Market Research
COVID-19 Pandemic Catalyzes the Transformation of the In-vitro Diagnostics Industry
Future Growth Potential is Enriched by Alternate Testing Sites in the Point-of-Care Testing Segment
This research service provides critical insights into the impact of COVID-19 on the global in-vitro diagnostics (IVD) industry, highlighting the growth opportunities, market revenue, and technology trends that influence its growth. Its three major segments identify the strategic imperatives of the IVD industry, the impact of COVID-19 on the IVD gro...
$2,450.00
Special Price $1,837.50 save 25 %
-
08 Nov 2016  |  North America  |  Market Research
The US Molecular Diagnostics Market, Forecast to 2021
Polymerase Chain Reaction (PCR) Holds Close to 53% Share but Strong Clinical Research will Push NGS to Revolutionize this Space in the Next 5 to 10 Ye
The US molecular diagnostics market is growing at 12.5% CAGR and is set to reach close to $6.5 billion by 2021. PCR, next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in this space with PCR holding more than 75% of the market. Roche, Cepheid, Qiagen, Abbott, and Thermo Fisher do...
$4,950.00
Special Price $3,712.50 save 25 %
-
19 Dec 2023  |  North America  |  Market Research
Growth Opportunities in US Digital Health Solutions as an Enabler for Value-based Care
Robust Investments and Disruptive Technological Innovation Transforming Care Delivery
According to the Centers for Medicare and Medicaid Services (CMS), value-based care (VBC) programs reward healthcare providers with incentive payments for the quality of care they provide Medicare patients. These programs are part of its larger CMS quality strategy to reform healthcare delivery and payment. Value-based programs support 3 aims: b...
$2,450.00
Special Price $1,837.50 save 25 %
-
23 May 2017  |  North America  |  Market Research
Growth Opportunities in the US In Vitro Diagnostics (IVD) Market, Forecast to 2021
US IVD Market Witnesses Pricing Fluctuations Due to the PAMA Regulation
The In Vitro Diagnostics (IVD) landscape in the United States is extremely dynamic, with a high level of merger and acquisition activity with many high-value deals still pending. Both clinical laboratories and manufacturers are increasingly vying for smaller specialized niche technology companies to increase their market share. Molecular point of c...
$4,950.00
Special Price $3,712.50 save 25 %
-
31 Jan 2024  |  North America  |  Market Research
Digital Health Regulations in North America and Europe: Growth Opportunities 2023
Innovative Business Models and Technologies are Leading to the Introduction of Disruptive Regulations
This report examines the regulations surrounding digital health in North America and Europe. It provides a general analysis of key national and regional regulatory updates that will impact digital health players and influence market dynamics. The regulatory documents considered are those governing the healthcare sector and applicable to digital hea...
$2,450.00
Special Price $1,837.50 save 25 %
-
17 Jul 2017  |  North America  |  Market Research
US Oncology Diagnostics Market, Forecast to 2021
Manufacturers Increase Assay Development Focus Toward Screening, Prevention, and Therapy Selection
Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual’s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolida...
$4,950.00
Special Price $3,712.50 save 25 %